By Cecilia Butini
Novartis AG said Monday that a Phase 3 trial to evaluate a drug for use in lung cancer patients didn't meet its primary endpoints.
The Swiss pharma major said the trial, named CANOPY-1, didn't demonstrate statistical significance in overall survival and progression-free survival, meaning the time that a patient can live without the disease progressing.
The trial evaluated canakinumab, a monoclonal antibody, in combination with chemotherapy for patients with non-small cell lung cancer.
Write to Cecilia Butini at cecilia.butini@wsj.com
